A lack of validated on-therapy ranges for the novel oral anticoagulants (NOACs) contributes to the difficulty in managing obese patients with conditions such as pulmonary embolism (PE) or deep vein thrombosis (DVT), a haematology meeting has heard. In addition, there is a lack of pharmacokinetic and clinical data to guide prescribing especially in patients at ...
Australian registry will grow evidence for anticoagulation in the obese
By Mardi Chapman
7 Nov 2018